Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22492Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Panagiotou, O. A. | en |
| dc.contributor.author | Contopoulos-Ioannidis, D. G. | en |
| dc.contributor.author | Papanikolaou, P. N. | en |
| dc.contributor.author | Ntzani, E. E. | en |
| dc.contributor.author | Ioannidis, J. P. | en |
| dc.date.accessioned | 2015-11-24T19:24:32Z | - |
| dc.date.available | 2015-11-24T19:24:32Z | - |
| dc.identifier.issn | 1525-1497 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22492 | - |
| dc.rights | Default Licence | - |
| dc.subject | Databases, Factual | en |
| dc.subject | Drug Labeling/methods/*standards | en |
| dc.subject | Humans | en |
| dc.subject | Pharmaceutical Preparations/*adverse effects/*classification | en |
| dc.subject | Safety-Based Drug Withdrawals/methods | en |
| dc.subject | United States | en |
| dc.subject | United States Food and Drug Administration/standards | en |
| dc.title | Different black box warning labeling for same-class drugs | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1007/s11606-011-1633-9 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21286838 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/031784796n7541kr/fulltext.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2011 | - |
| heal.abstract | INTRODUCTION: Black box warnings (BBWs) are the strongest medication-related safety warnings in a drug's labeling information and highlight major risks. Absence of a BBW or asynchronous addition of a BBW among same-class drugs could have major implications. METHODS: We identified the 20 top-selling drugs in 2008 (10 with BBWs and 10 without BBWs on their label) that belonged to different drug classes. We collected labeling information on all drugs belonging in these 20 classes, and recorded differences in the presence and timing of acquisition of BBWs for same-class drugs. RESULTS: Across the 20 evaluated drug classes, we identified 176 different agents, of which 7 had been withdrawn for safety reasons. The reasons for the withdrawals became BBWs in other same-class agents only in two of the seven cases. Differences were identified in 9 of the 20 classes corresponding to 15 BBWs that were not present in all drugs of the same class. The information for 10 of the 15 different BBWs were included in the labels of same-class drugs as simple warnings or text, while it was absent entirely in 5 BBWs. The median interval from the time the BBW had appeared in another drug of the same class was 66 months. DISCUSSION: Differences in BBW labeling in same-class drugs are common and shape impressions about the safety of similar agents. BBW labeling needs to become more systematic. | en |
| heal.journalName | J Gen Intern Med | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Panagiotou-2011-Different black box.pdf | 174.92 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
